Latest News

As the Canadian market navigates through a period of uncertainty, with central banks offering limited guidance on future policy directions, investors are keeping a close eye on economic indicators to gauge potential interest rate cuts. In such volatile times, penny stocks—despite their somewhat outdated moniker—remain an intriguing investment area due to their affordability and growth potential. These smaller or newer companies can offer significant returns when backed by strong financials,...

Key Insights The projected fair value for Meridian Energy is NZ$9.21 based on 2 Stage Free Cash Flow to Equity Current...

Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...

Koninklijke Ahold Delhaize’s consensus analyst price target has seen only a slight increase, moving from €35.90 to €36.47. Analysts remain divided, with some cautious voices citing margin pressures and competitive challenges. Others highlight ongoing resilience and disciplined management as reasons to support the stock’s valuation. Stay tuned to discover how you can keep up with the evolving narrative around Ahold Delhaize’s market outlook. What Wall Street Has Been Saying Analyst commentary...

Thinking about what to do with Corpay stock? You are not alone; it has been a hot topic ever since recent price swings caught the attention of both cautious investors and growth optimists. Over just the past week, Corpay saw its shares dip by 2.7%, and that slide stretches to a 10.0% drop for the last 30 days. Year-to-date, the stock is down 12.3%. These moves might have some people concerned, but to put things in perspective, Corpay has still returned a solid 70.9% over three years, along...

As major U.S. stock indexes experience declines, particularly in the tech sector, and energy stocks outperform due to rising crude futures, investors are keenly observing market fluctuations and valuations. In this environment, growth companies with strong insider ownership can be appealing as they often signal confidence from those closest to the business.

As the U.S. stock market experiences a mixed performance with tech shares declining and the energy sector outperforming, investors are exploring diverse opportunities to navigate these fluctuating conditions. Penny stocks, despite their somewhat outdated name, continue to attract attention due to their potential for significant returns when backed by solid financials. This article examines three penny stocks that stand out for their financial strength and potential for growth, offering...

Nu Skin Enterprises recently reported progress in operational efficiency, innovation, and international expansion, highlighted by growth in its Rhyz Manufacturing segment and anticipation for the AI-powered Prysm iO device. This operational momentum is fueling greater user interest, especially as product innovation and technology integrations shape future customer engagement. We’ll explore how the upcoming Prysm iO device supports Nu Skin Enterprises’ investment narrative and potential for...

Despite an already strong run, Alibaba Group Holding Limited ( NYSE:BABA ) shares have been powering on, with a gain of...

If you've been watching Kingsgate Consolidated (ASX:KCN), the last few days may have caught your attention. The company has just been added to both the S&P/ASX Small Ordinaries Index and the S&P/ASX 300 Index, two moves that often lead to fresh investment flows and shine a brighter spotlight on a stock. With Kingsgate set to present at the upcoming ASX SMIDcaps Conference, the stage seems set for more updates, which could potentially influence how the market views its growth prospects. These...

So, you’ve been following Zijin Mining Group (SEHK:2899) and are wondering if now is the time to make a move. The company just hit a major milestone, launching production at its Tres Quebradas lithium project in Argentina. This isn’t just a ribbon-cutting moment; it marks Zijin stepping further into the global battery materials space at a time when demand for electric vehicle batteries is hitting new highs. With over USD 600 million invested in development since acquiring the asset in 2022,...

Ypsomed Holding has seen its consensus analyst price target dip from CHF463.26 to CHF449.37, reflecting mixed analyst sentiment. Recent commentary highlights both bullish confidence in Ypsomed's leadership in the injectable market, as well as caution from others who question the sustainability of its growth following a company transformation. Stay tuned to discover how you can keep up with shifts in the evolving narrative for Ypsomed Holding stock. What Wall Street Has Been Saying Analyst...

In September 2025, Aquestive Therapeutics announced that the FDA will not require an advisory committee meeting for its Anaphylm sublingual epinephrine film, clearing a smoother regulatory path toward a potential launch. This decision signals increased confidence in both the product's regulatory prospects and the potential for accelerated adoption of needle-free epinephrine treatments. We'll explore how this clear regulatory pathway for Anaphylm could reshape Aquestive Therapeutics'...

With a price-to-earnings (or "P/E") ratio of 12.1x Boyd Gaming Corporation ( NYSE:BYD ) may be sending bullish signals...

Steven Madden’s consensus analyst price target has recently risen from $28.12 to $30.00, reflecting a shift in analyst sentiment. This update suggests increased confidence in the company’s near-term outlook, partly because of faster inventory turnover and operational improvements. Stay tuned to discover how ongoing market developments may continue to influence the narrative for Steven Madden stock. What Wall Street Has Been Saying Steven Madden’s stock has drawn increased attention from Wall...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Porch Group’s consensus analyst price target has jumped significantly, rising from $14.00 to $19.75 in the latest update. Much of this optimism is driven by robust revenue growth forecasts, now climbing to 14.4% per annum. As sentiment shifts, it is essential to stay informed to understand where analysts see this evolving narrative heading next. What Wall Street Has Been Saying Analyst commentary on Porch Group has intensified following the company’s strong recent performance and updated...

JPMorgan Chase & Co. ( NYSE:JPM ) has announced that it will be increasing its dividend from last year's comparable...

Halozyme Therapeutics has recently seen its consensus analyst price target edge upward, moving only narrowly from $70.56 to $71.67. This modest increase comes as analysts weigh improved earnings projections against ongoing regulatory uncertainties. The result is a balanced shift in sentiment. Stay tuned to discover strategies for keeping pace with future updates to Halozyme's evolving investment narrative. What Wall Street Has Been Saying Analyst commentary on Halozyme Therapeutics reflects a...

Regis Healthcare (ASX:REG) just got everyone's attention following a steep 26% drop in its share price. The trigger? A company update revealed that the Australian Government’s latest funding boost for aged care will fall short of what Regis had anticipated. The funding gap means that recent increases will not fully cover higher staffing and wage costs, which puts immediate pressure on profit margins and casts a shadow over near-term earnings prospects. This kind of move is tough to ignore,...

It seems like plenty of investors are keeping a close eye on Vanguard Index Funds, specifically the Vanguard S&P 500 ETF (VOO), these days, and for good reason. With no specific headline grabbing the spotlight, the subtle shifts in VOO’s performance might leave you wondering if we are looking at the start of a new trend or just a pause in what has already been an impressive run. The real question is what, if anything, these recent moves signal about the ETF’s underlying value—and if there is...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

The consensus analyst price target for Workday stock has held steady, shifting only marginally from $279.05 to $282.05. This minimal movement reflects a balance of optimism about the company's AI-driven initiatives, as well as persistent concerns around macroeconomic and competitive pressures. Stay tuned to discover how you can stay informed about these evolving dynamics and the future narrative surrounding Workday's stock. What Wall Street Has Been Saying Recent analyst commentary on Workday...

So, you are eyeing Nexi stock and wondering where it stands, either as an opportunity to buy on the dip or as a cautionary tale of catching a falling knife. To be fair, the last five years have not been particularly kind to Nexi shareholders, with the stock down a hefty 70.4% in that timeframe. Even in the last year alone, Nexi has declined by 19.8%, and so far this year it is still down about 11.7%. If you zoom in a bit closer, the picture is more nuanced: while last week brought a modest...